Saredutant
Saredutant is a drug that was under development by Sanofi-Aventis for the treatment of anxiety and depression. It acts as a selective neurokinin 2 receptor antagonist.
History[edit | edit source]
Saredutant was first developed by the French multinational pharmaceutical company Sanofi-Aventis. The drug was in the late stages of clinical trials for the treatment of anxiety and depression, but development was discontinued in 2009.
Mechanism of Action[edit | edit source]
Saredutant works by selectively blocking neurokinin 2 receptors. These receptors are found in the brain and are involved in the regulation of mood and anxiety. By blocking these receptors, Saredutant can potentially reduce symptoms of anxiety and depression.
Clinical Trials[edit | edit source]
Several clinical trials were conducted to assess the efficacy and safety of Saredutant. These trials showed promising results, with Saredutant demonstrating a significant reduction in symptoms of anxiety and depression compared to placebo. However, the development of the drug was discontinued before it could be approved for use.
Discontinuation[edit | edit source]
The development of Saredutant was discontinued in 2009. The reasons for this are not publicly disclosed, but it is speculated that the decision was based on a combination of factors including the results of the clinical trials, the potential market for the drug, and the company's overall strategic direction.
See Also[edit | edit source]
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD